Document Detail

Correlation between the aPTT and clinical events in acute coronary syndromes treated with unfractionated heparin.
MedLine Citation:
PMID:  17425158     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The primary objective of this study is to analyse relationship between activated partial thromboplastin time (aPTT) and clinical events in patients with unstable coronary artery disease. BACKGROUND: Unfractionated heparin (UFH) is considered as a standard therapy in the management of unstable coronary artery disease. His efficacy is concerned to low rate of adverse events, but it shows lack of correlation between aPTT and clinical outcomes. METHODS: Thirty patients with acute coronary syndromes were randomised to receive weight-adjusted unfractionated heparin (Heparin-"Biochemie" 25.000 IU/5 ml), according to Rashke nomogram. Six hours after the initial bolus dose, the aPTT was measured and the heparin infusion was adjusted. Relationship between the aPTT and the day of onset of recurrent angina (RA), myocardial infarction (MI), heart failure (HF), death, and target vascular revasularization (TVR) during six months follow-up was evaluated. RESULTS: At 6 h, 40 % of patients achieved the target level of aPTT (60-85 sec). Also, 40 % patients were below the target range, 41.6 % had aPTT less than 30 sec and 20 % were above the target range. We noted significant difference between heparin dosing and aPTT (p=0.0000). But we did not find significant difference between aPTT and outcomes as RA and MI (p=1.0, p=0.42). Pearson Product Moment Correlation shows negative correlations between aPTT and the day of onset of RA (r=-0.05) and TVR (r=-0.23), and pozitive correlations for MI (r=0.35) and death (r=0.87). CONCLUSION: The level of aPTT shows discordance with the onset of clinical events and is a weak predictor of outcomes (Tab. 2, Fig. 7, Ref 5).
S Mitrovska; S Jovanova
Related Documents :
8287868 - Thrombolysis: state of the art.
14156828 - Initial heparin therapy in acute myocardial infarction.
12063808 - Glycoprotein iib/iiia antagonism and fibrinolytic therapy for acute myocardial infarction.
17124018 - Bivalirudin for patients with acute coronary syndromes.
8916018 - The determination of myocardial viability using gd-dtpa in a canine model of acute myoc...
10952838 - A national survey of acute myocardial infarction and ischaemia (samii) in the u.k.: cha...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Bratislavské lekárske listy     Volume:  107     ISSN:  0006-9248     ISO Abbreviation:  Bratisl Lek Listy     Publication Date:  2006  
Date Detail:
Created Date:  2007-04-11     Completed Date:  2007-06-07     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0065324     Medline TA:  Bratisl Lek Listy     Country:  Slovakia    
Other Details:
Languages:  eng     Pagination:  422-5     Citation Subset:  IM    
Department of Cardiology, Military Hospital, Skopje, Macedonia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina, Unstable / blood,  drug therapy*
Anticoagulants / therapeutic use*
Heparin / therapeutic use*
Myocardial Infarction / blood,  drug therapy*
Partial Thromboplastin Time*
Treatment Outcome
Reg. No./Substance:
0/Anticoagulants; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Systematic isolation and characterization of cDNAs encoding AAA proteins from human brain.
Next Document:  Valsalva leak point pressure predicts outcome after transobturator suburethral tape implantation--fa...